Showing results (21-30 of 45) with videos related to
Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint InhibitorsAdam C Palmer, Benjamin Izar, Haeun Hwangbo, et al.Transcription|January 28, 2017
Directing traffic on DNA-How transcription factors relieve or induce transcriptional interferenceNan Hao, Adam C Palmer, Ian B Dodd, et al.Blood Cancer Discovery|January 17, 2024
Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid LeukemiaEmily Mason-Osann, Amy E Pomeroy, Adam C Palmer, et al.Trends in Cancer|July 16, 2022
Drug independence and the curability of cancer by combination chemotherapyAmy E Pomeroy, Emmett V Schmidt, Peter K Sorger, et al.Nature Cancer|November 17, 2023
Additivity predicts the efficacy of most approved combination therapies for advanced cancerHaeun Hwangbo, Sarah C Patterson, Andy Dai, et al.Nature Communications|February 16, 2022
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effectsDeborah Plana, Geoffrey Fell, Brian M Alexander, et al.Nucleic Acids Research|July 6, 2016
The role of repressor kinetics in relief of transcriptional interference between convergent promotersNan Hao, Adam C Palmer, Alexandra Ahlgren-Berg, et al.FEBS Letters|March 21, 2019
RNA polymerase pausing at a protein roadblock can enhance transcriptional interference by promoter occlusionNan Hao, Michael T Crooks, Adam C Palmer, et al.Cancer Research Communications|June 1, 2026
Additivity, not synergy, underlies the efficacy of current combination regimens in urothelial cancerNoah M Schlachter, Eric J Miller, Jonathan F Anker, et al.Nature Communications|June 11, 2015
Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapesAdam C Palmer, Erdal Toprak, Michael Baym, et al.Pageof 5